SeptiCyte® is Our Pioneering Technology for Fast and Accurate Sepsis Diagnosis
Our Technology Rapidly Quantifies Specific Biomarkers to Aid Clinicians in the Early Identification of Infection in Suspected Sepsis Patients.
By testing whole blood directly, the assay is able to detect the response of the patient’s immune system to an infection earlier, faster and more accurately than finding the pathogen. To learn more about SeptiCyte® RAPID, visit https://septicyte.com/
Understanding Host Response to Create Better Diagnostic Tools
The traditional approach to determining infection status in suspected sepsis patients focuses on identifying and characterizing the invading pathogen.
The Problem
Detecting the pathogen is often slow, and in most suspected sepsis cases, the pathogen is not identified.
The Insight
The immune system produces a specific and abundant genetic signal in response to an invading pathogen, which can be reliably detected.
The Solution
SeptiCyte® RAPID enhances sepsis diagnosis and treatment by analyzing immune cells' RNA, which offers a measurable snapshot of the host's immune response.
The Result
Our algorithm quantifies the patient's immune response to sepsis and rapidly provides actionable clinical information in 100% of suspected sepsis cases.
Revolutionizing Sepsis Diagnosis with SeptiCyte® RAPID
SeptiCyte® RAPID was developed to empower clinicians to provide the most effective sepsis care management, by using specific biomarkers in the patient’s immune system to measure dysregulated immune response signals that indicate sepsis.
SeptiCyte® RAPID has CE mark for Europe, TGA for Australia and received FDA market clearance as the first one hour direct from blood sepsis test.
SeptiCyte® RAPID is a PCR-based test for sepsis designed to differentiate non-infectious systemic inflammatory response syndrome (SIRS) from sepsis in critically ill patients, providing an estimate of the likelihood of sepsis, the SeptiScore®.
SeptiCyte® RAPID achieves this with high accuracy and superior performance to clinical parameters and other lab tests.
This sepsis test uses a small volume of blood and can be performed easily in any hospital lab with Biocartis IdyllaTM platform. SeptiCyte® RAPID revolutionizes sepsis diagnosis and treatment, by providing actionable results in about an hour.
The IdyllaTM System
Clinicians are working against the clock when treating sepsis. Our goal is to transform sepsis diagnostics by providing clinicians with the technology to rapidly enable and confidently make the right treatment decisions.
In January 2018, we announced a partnership with Biocartis to develop and commercialize a fully automated SeptiCyte® LAB test for use on the Biocartis’ sample-to-answer real-time PCR Idylla™ platform.
Diagnose Sepsis With More Certainty in About One Hour
SeptiCyte® RAPID addresses the unmet need for a rapid, sensitive, and reliable diagnostic test to provide physicians with actionable results to rule out sepsis with high confidence, or to expedite preventative action with prompt therapeutic interventions.
SeptiCyte® cartridges are formatted to work with the Biocartis IdyllaTM platform, a fully automated, RT- PCR based molecular testing system designed to offer fast and easy access to molecular biomarker information. Its compact scalable design and outstanding ease of use allows it to be used in virtually any laboratory setting.
For more information about the IdyllaTM solution please visit biocartis.com.
Introducing SeptiCyte® RAPID, A Revolutionary Way to Diagnose Sepsis.
Rule In/Out Sepsis
- Measures host response to systemic infection by PCR
- mRNA signature from blood
- High NPV and high PPV to differentiate
Actionable Results in About 1 Hour
- 1 step sample to result
- Rapid assay turnaround time
Ease of Use
- Fully automated sample to result process
- All reagents integrated in single-use cartridge
- 2-minute hands-on time
Result as Probability Risk Score (SeptiScore®)
- Result interpretation via 4 probability bands
- The SeptiScore® correlates with sepsis risk
Increased Laboratory Service Level
- Minimize need for additional diagnostic tests
- Early sepsis rule out to obviate pathogen ID test
SeptiCyte® RAPID Workflow on the IdyllaTM Platform
SeptiCyte® RAPID is designed for ease of use and rapid, accurate results in about an hour.
Learn more about SeptiCyte® RAPID lab test for sepsis on the IdyllaTM Platform
SeptiCyte® RAPID provides the technology to radically accelerate treatment decisions by providing rapid, accurate diagnosis of sepsis. SeptiCyte® RAPID and the IdyllaTM Platform allow for a user-friendly, fully-automated system to test for sepsis.
Patents & Pipeline
Immunexpress has granted patents and applications in key markets that cover sepsis diagnostic technology measuring the host immune response. Claims include biomarkers, algorithms, analysis methods, treatments, compositions and kits.
These patents include combinations of biomarkers for differentiating sepsis and SIRS, diagnosing bacterial, viral, herpes and protozoal infections, and differentiating pathogenic bacteria.
The Immunexpress product pipeline includes expanded applications for SeptiCyte® RAPID, including regulatory clearance for use in pediatrics and a second generation test, SeptiCyte® RAPID+, a nine gene expression assay to differentiate sepsis vs SIRS and differentiate bacterial vs viral sepsis in hospitalized patients within approximately 70 minutes.